KDOQI临床操作指南的系统综述.pdf

Original Investigation Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline Yelena Slinin, MD, MS,1,2 Areef Ishani, MD, MS, 1,2 Thomas Rector, PhD,1 Patrick Fitzgerald, MPH,1 Roderick MacDonald, MS,1 James Tacklind, BS, 1,2 Indulis Rutks, BS,1 and Timothy J. Wilt, MD, MPH 1,2 Background: In 2007, the National Kidney Foundation (NKF) published clinical practice guidelines and recommendations for treating patients with diabetes and kidney diseases. Given recent studies that may enhance our understanding of the benefits and harms of glycemic, lipid, and albuminuria management in patients with diabetes and chronic kidney disease (CKD), the NKF commissioned a systematic review to evaluate data on the management of these patients. Study Design: Systematic review and evidence synthesis. Setting Population: Patients with type 1 or 2 diabetes with or without CKD. Selection Criteria for Studies: English-language publications indexed in the MEDLINE database from January 2003 to October 2010, as well as cited references in these publications and publications identified after consultation with the NKF Diabetes Work Group were screened. Randomized controlled trials providing evidence for the management of hyperglycemia, dyslipidemia, and albuminuria in individuals with diabetes were included. Interventions: (1) Intensive glycemic control; (2) lipid management; (3) interventions aimed at prevention of incident albuminuria and/or progression of albuminuri